New Alzheimer’s Drug

Alzheimer’s disease causes the cells in the brain to get sick and eventually die, which leads to symptoms like memory loss.

Lecanemab (sometimes called BAN2401, and marketed under the name Leqembi) is a immunotherapy drug, developed by the pharmaceutical company Eisai. It is designed for people living with early-stage Alzheimer’s disease and is given to patients by an intravenous drip. It has already been shown to be effective at slowing the progression of Alzheimer’s disease, and has already been approved in the US, with decisions by the EU and UK regulators due in 2024.

We have customers who are under Alzheimer’s care in Central Bedfordshire by our lovely care workers and this has given a ray of hope with the new drug that has been introduced in the USA. We at Caremark central Bedfordshire, a homecare provider in Dunstable applaud this new discovery!!